ArticleAnnals of medicine2026
Prognostic value of peak tricuspid regurgitation velocity in hospitalized patients with heart failure with preserved ejection fraction: an multi-institutional study.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHeart failure with preserved ejection fraction (HFpEF) represents a significant clinical challenge with limited prognostic markers. The prognostic value of Doppler-derived peak tricuspid regurgitation velocity (TRVmax) in HFpEF patients remains underexplored.
methodsThis retrospective cohort study analysed 6,438 patients with HFpEF hospitalized for acute heart failure between 2007 and 2018. Patients were stratified into three groups based on baseline TRVmax values: ≤2.8 m/s, 2.9-3.4 m/s and >3.4 m/s. The primary outcome was a composite of heart failure rehospitalization and cardiovascular mortality. Association between TRVmax levels and the risks of outcome was evaluated using Cox proportional hazards model with adjustment for established risk factors.
resultsDuring the median follow-up of 2 years (interquartile range: 0.8-4 years), increasing incidence rates of the composite outcome were observed across the three groups (17.8, 21.2 and 23.9 per 100 person-years, respectively). Compared to the TRVmax ≤2.8 m/s group, significantly higher risks were observed in the TRVmax 2.9-3.4 m/s group (adjusted HR: 1.11, 95% CI: 1.003-1.22) and TRVmax >3.4 m/s group (adjusted HR: 1.23, 95% CI: 1.09-1.39). Each 0.5 m/s increase in TRVmax was associated with a 7% increase in composite outcome risk (HR: 1.07, 95% CI: 1.04-1.10).
conclusionsTRVmax exceeding 2.8 m/s has prognostic value for heart failure rehospitalization and cardiovascular mortality in HFpEF patients, suggesting its potential utility as a risk stratification tool in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.